2'-deoxy-2'-[18F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck.

Oncotarget 2018 Jun 19;9(47):28572-28585. Epub 2018 Jun 19.

Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université catholique de Louvain, Brussels, Belgium.

We investigated changes on 2'-deoxy-2'-[18F]fluoro-D-glucose positron emission tomography (FDG-PET), diffusion-weighted magnetic resonance imaging (DW-MRI), and choline spectroscopy as early markers of cetuximab activity in squamous cell carcinoma of the head and neck (SCCHN). SCCHN patient-derived tumor xenografts models were selected based on their cetuximab sensitivity. Three models were resistant to cetuximab and two were sensitive (one was highly sensitive and the other one was moderately sensitive). Cetuximab was infused on day 0 and 7. Maximal standardized uptake values (SUVmax), apparent diffusion coefficient (ADC), and total choline pool were measured at baseline and at day 8. To investigate the possible clinical relevance of our pre-clinical findings, we also studied the SUVmax and ADC modifications induced by cetuximab in five patients. Cetuximab induced a significant decrease in SUVmax and an increase in ADC at day 8 compared to baseline in the most cetuximab-sensitive model but not in the other models. At day 8, in one resistant model, SUVmax was decreased compared to baseline and was significantly lower than the controls. Choline spectroscopy was not able to predict cetuximab activity. The five patients treated with cetuximab had a FDG-PET partial response. One patient had a partial response according to RECISTv1.1. Interestingly, this last had also an increase in ADC value above 25%. Our preclinical data support the use of PDTX to investigate imaging techniques to detect early treatment response. Our pre-clinical and clinical data suggest that DW-MRI and FDG-PET should be further investigated to predict cetuximab activity.

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.25574DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033354PMC
June 2018
19 Reads

Publication Analysis

Top Keywords

choline spectroscopy
12
cetuximab activity
12
cetuximab
10
head neck
8
predict cetuximab
8
carcinoma head
8
cell carcinoma
8
partial response
8
tumor xenografts
8
squamous cell
8
magnetic resonance
8
spectroscopy predict
8
resonance imaging
8
increase adc
8
emission tomography
8
diffusion-weighted magnetic
8
positron emission
8
compared baseline
8
adc day
4
modifications induced
4

Similar Publications